http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Mina Neghabi,Abbas Behjat,Bi Bi Fatemeh Mirjalili,Leila Zamani 한국물리학회 2013 Current Applied Physics Vol.13 No.1
One of the porphyrin derivatives, meso-tetraphenylporphyrin (TPP), has been synthesized and examined as an emitter material (EM) for efficient fluorescent red organic light-emitting diodes (OLEDs). By inserting a tungsten oxide (WO3) layer into the interface of anode (ITO) and hole transport layer N,N0-Di-[(1-napthyl)-N,N0-diphenyl]-(1,10-biphenyl)-4,40-diamine (NPB) and by using fullerene (C60) in contact with a LiF/Al cathode, the performance of devices was markedly improved. The current densityevoltageeluminance (JeVeL) characterizations of the samples show that red OLEDs with both WO3 and C60 as buffer layers have a lower driving voltage and higher luminance compared with the devices without buffer layers. The red OLED with the configuration ITO/WO3 (3 nm)/NPB (50 nm)/TPP (60 nm)/BPhen (30 nm)/C60 (5 nm)/LiF (0.8 nm)/Al (100 nm) achieved the high luminance of 6359 cd/m2 at the low driving voltage of 8 V. At a current density of 20 mA/cm2, a pure red emission with CIE coordinates of (0.65; 0.35) is observed for this device. Moreover, a power efficiency of 2.07 lm/W and a current efficiency of 5.17 cd/A at 20 mA/cm2 were obtained for the fabricated devices. The study of the energy level diagram of the devices revealed that the improvement in performance of the devices with buffer layers could be attributed to lowering of carrier-injecting barrier and more balanced charge injection and transport properties.
Monabati, Ahmad,Vahedi, Amir,Safaei, Akbar,Noori, Sadat,Mokhtari, Maral,Vahedi, Leila,Zamani, Mehdi Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.4
Background: Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL) of the elderly is an entity introduced in the latest WHO classification of lymphoid tumors and defined in patients older than 50 years without prior lymphoma or immunodeficiency. However, recently it has also been seen in patients under 50. There is thus debate as to whether these are separate entities. Materials and Methods: In this retrospective study, we analyzed de novo DLBCL admitted to our institute over a period of two years. Clinical data included age, sex, nodal and extranodal presentation. The results of an immunohistochemistry (IHC) panel were also reviewed. IHC findings were mainly used to sub-classify DLBCL as germinal center vs. non germinal center types. IHC for identification of LMP-1 (latent membrane protein) and in situ hybridization for detection of EBV-encoded RNA (EBER) was performed. EBV prevalence, clinical data and IHC findings were compared between patients under and over 50 years of age. Results: Out of 95 DLBCL, 11.6% were EBV positive (7.5% and 14.5% in the young and old groups). We did not find any significant differences in IHC subclasses and clinical data between EBV positive DLBCL (EBV+DLBCL) of young and old groups. Conclusions: EBV+DLBCL are not exclusive to patients older than 50 years. With regard to clinical data as well as IHC subclasses, no differences were evident between EBV+DLBCL of young and old groups. Our suggestion is to eliminate any cut off age for EBV+DLBCL.